Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Abstinence-Linked Money Management Multisite

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT01327586
First received: February 2, 2011
Last updated: July 16, 2014
Last verified: July 2014

February 2, 2011
July 16, 2014
December 2009
January 2014   (final data collection date for primary outcome measure)
Proportion of Urine toxicology tests without cocaine [ Time Frame: Month 0,1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01327586 on ClinicalTrials.gov Archive Site
Unprotected sexual encounters [ Time Frame: Month 0, 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ] [ Designated as safety issue: No ]
ACASI-measured
Same as current
Not Provided
Not Provided
 
Abstinence-Linked Money Management Multisite
Abstinence-Linked Money Management Multisite

Randomized clinical trial comparing a money management-based intervention involving storage and management of client funds, substance abuse counseling, and risk reduction counseling to individualized drug counseling.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
  • Dual Diagnosis
  • Cocaine Abuse
  • Cocaine Dependence
  • Polysubstance Abuse
  • Behavioral: ATM
    Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
  • Behavioral: Individual Drug Counseling
    Standard individualized drug counseling, modified from that described by Woody and colleagues
  • Experimental: ATM
    Advisor-Teller Money Manager
    Intervention: Behavioral: ATM
  • Active Comparator: Individual Drug Counseling
    Intervention: Behavioral: Individual Drug Counseling
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
108
January 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Enrolled in ambulatory psychiatric treatment at one of the participating clinics
  • Receives SSI or SSDI payments
  • Able to provide written informed consent
  • Cocaine use within the last 60 days as evidenced by either a positive toxicology screen or self-reports

Exclusion Criteria:

  • Has a conservator of person
  • A history of violence towards clinical providers or predatory violence
  • Suicidal plans or intent; homicidal plans or intent. Suicidal or homicidal ideation will not be exclusion criteria
  • Physiological dependence on alcohol, illicit opiates or illicit sedatives as evidenced by a history of four weeks of daily use of these substances; and either tolerance or withdrawal (as defined by DSM IV-TR). The "standard withdrawal scales" referred to in DSM IV-TR will be the CIWA-AR (Sullivan et al., 1989) and the Clinical Opiate Withdrawal Scale (Wesson and Ling, 2003), with P.I. review because signs on the CIWA-AR such as "aware of sounds around you" may reflect psychiatric illness, not withdrawal
  • Will not be able to complete the twelve months of the study because of anticipated incarceration or move
  • Had been enrolled in the ongoing study
  • Unable to speak and understand English
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01327586
R01DA12952 from VACHS account
Yes
Yale University
Yale University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Marc I Rosen, M.D. Yale University
Yale University
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP